AUTHORS
Anna Skwarska, PhD, Ilaria Iacobucci, PhD2, Andy Zeng, MD, PHD3, Shikhar Sharma, PhD4, Sovira Chaudhry, MS5, Gowri Poigaialwar, PhD6, Francesca Benini7, Prady Baviskar, PhD, DVM8, Pankaj Ghate, PhD9, Qingsong Gao, PhD10, Emily Backhaus11, QI Zhang Tatarata, MD, PhD12, Zhe Wang13, Varun Gupta14, Katarzyna Anna Szoltysek, PhD15, John E. Dick, PhD16, Charles G. Mullighan, MBBS (Hons), MSc, MD17, Daohong Zhou, MD18, Marina Konopleva, MD, PhD19
AFFILIATIONS
1 Albert Einstein College of Medicine, Bronx, New York, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Albert Einstein College of Medicine, Bronx, New York, United States
5 Albert Einstein College of Medicine, Bronx, New York, United States
6 Albert Einstein College of Medicine, Bronx, New York, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 Houston Methodist The Woodland Hospital, Houston, Texas, United States
13 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
14 Albert Einstein College of Medicine, Bronx, New York, United States
15 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
16 University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
17 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
18 The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
19 Albert Einstein College of Medicine, Bronx, New York, United States
ABSTRACT
Introduction: Acute erythroleukemia (AEL) is a rare (~5%) and highly aggressive subtype of acute myeloid leukemia (AML), characterized by a high percentage of malignant erythroid progenitors and erythroblasts, complex karyotype and bi-allelic TP53 mutations. AEL patients exhibit very poor responses to available therapies with median overall survival < 6 months. While the BCL-2 inhibitor venetoclax (VEN) combined with hypomethylating agents (HMAs) has improved outcomes in older or unfit patients with AML, its efficacy remains limited in adverse-risk TP53-mutated AML. Emerging clinical data demonstrate that AEL is highly refractory to VEN/HMAs-based regimens (Reichard et al. Blood Cancer J 2022), underscoring the urgent need for novel targeted therapies. Recent studies identified anti-apoptotic BCL-xL as a selective vulnerability in AEL and demonstrated overexpression of BCL2L1 (encoding BCL-xL) in erythroid and megakaryocytic AML (Kuusanmäki et al. Blood 2023). In addition, frequent EPOR/JAK2 gains and amplifications with downstream upregulation of STAT5 activation in TP53-mutated AEL, implicate JAK/STAT signaling as a therapeutic dependency in this disease (Iacobucci et al. Nat Genet 2019). Here, we investigate BCL-xL and JAK/STAT signaling as survival vulnerabilities in AEL and demonstrate synergy between BCL-xL PROTAC DT2216 and JAK2 inhibitor ruxolitinib.
Results: Analysis of RNA-seq data from adult/pediatric AEL cohort (n=159) showed high expression of BCL2L1 across all genomic AEL subtypes, including mutated TP53, NPM1, KMT2A, NUP98, and DDX41 cases. In the St. Jude/TARGET pediatric AML cohort (n=553; Umeda et al. Nat Genet 2024), BCL2L1 expression was markedly higher in AEL compared with other AML subtypes, suggesting that BCL-xL may represent a potential therapeutic target. Recent scRNA-seq analysis defined twelve differentiation states in AML (Zeng et al. BCD 2025). Quantification of these differentiation states within bulk RNA-seq profiles of 1,224 AML patients revealed that BCL2L1 expression was enriched in early/late erythroid-like cell states and strongly correlated with transcription factor GATA1, an activator of BCL2L1. Notably, BCL2L1 expression was highest in AEL and transcriptionally defined “AEL-like” cases that were not identified by conventional morphologic evaluation and flow cytometric immunophenotyping. Additionally, enrichment of the constitutive STAT5A overexpression signature correlated with BCL2L1 expression in AML/AEL bulk RNA-seq datasets and was higher in AEL compared with other AML subtypes. In vitro, BH3 profiling in cell lines revealed selective BCL-xL, but not BCL-2, dependency of AEL cell lines (TF-1 and F36P) and primary TP53-mutated AEL sample. Consistently, CRISPR/Cas9 knockout of BCL2L1 impaired AEL cells viability while sparing non-AEL THP1 cells. DT2216 effectively degraded BCL-xL at low nanomolar doses and reduced viability of VEN-refractory AEL cells (TF-1, F36P and HEL-1) and primary samples from VEN-resistant TP53-mutated R/R AEL patients. Combinations of DT2216 with HMAs (5-AZA and decitabine) resulted in synergistic activity in AEL cell lines. Similarly, DT2216 synergized with JAK2 inhibitor ruxolitinib across AEL models including TF-1 and HEL-1 cells, ex vivo cultures from CRISPR/Cas9 engineered mouse model (Trp53/Bcor/Rb1/Kras, Iacobucci et al. Blood 2021), and human TP53-mutated AEL PDX. Preliminary in vivo studies showed that DT2216 produced significant anti-leukemic effect in a primary AEL PDX (alterations in SF3B1, IKZF1, CBL, RUNX1), markedly reduced leukemia burden and significantly prolonged survival. Importantly, DT2216 achieved near-complete BCL-xL degradation in AEL cells isolated from spleens after two doses, confirming on target engagement in vivo. Finally, genome-wide CRISPR screen in TF-1 cells treated with DT2216 identified new synthetically lethal dependencies in OXPHOS/redox pathway, iron-sulfur biology, or nucleotide metabolism. Pharmacological inhibition of nucleotide metabolism with immunosuppressant mycophenolate mofetil or iron depletion with deferasirox, demonstrated synergistic cytotoxicity with DT2216, identifying potential combination strategies for BCL-xL targeting in AEL.
Conclusions: Our studies validate BCL-xL as a key vulnerability in AEL and provide strong preclinical evidence supporting combined BCL-xL degradation with DT2216 and JAK2 inhibition with ruxolitinib as a novel treatment strategy for this highly aggressive AML subtype.
DISCLOSURES
Anna Skwarska, PhD: No relevant conflicts of interest to declare.